{"id":"W4399361197","doi":"10.1007/s10637-024-01448-w","title":"A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal; Crosslight Software (Canada); University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Nausea; Adverse effect; Medicine; Vomiting; Pharmacokinetics; Internal medicine; Pharmacology; Gastroenterology; Refractory (planetary science); Dosing; Tolerability; Toxicity; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001713882,0.0001983986,0.0002200923,0.0001412603,0.00004503442,0.0000251418,0.0001001184,0.0001117351,0.0000165565],"category_scores_gemma":[0.0000489297,0.0001874021,0.00004994449,0.0001841723,0.0001813719,0.00002457089,0.00003405839,0.0001453129,0.000002280524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004324258,"about_ca_system_score_gemma":0.0005493913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001123719,"about_ca_topic_score_gemma":0.0001160078,"domain_scores_codex":[0.9986674,0.00006376793,0.0004029205,0.0004081151,0.0002471454,0.0002106629],"domain_scores_gemma":[0.9995284,0.00003284271,0.00007415919,0.000159899,0.0000487744,0.000155941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.06215683,0.006013438,0.03083991,0.001545253,0.0001669298,0.0001694157,0.008745435,0.001243874,0.86563,0.003821094,0.003743951,0.0159239],"study_design_scores_gemma":[0.3157763,0.0131387,0.008596138,0.001372998,0.0000712236,0.00001284302,0.0002770853,0.0005146515,0.6369167,0.006727617,0.01527513,0.00132066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982003,0.0005276445,0.00003561021,0.0001362223,0.00009219107,0.0005454343,0.00009394332,0.00001441219,0.0003542184],"genre_scores_gemma":[0.9984263,0.00002999545,0.0007239485,0.0001197,0.0001093459,0.00005151982,0.0003551772,0.00003044539,0.0001535558],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2536194,"threshold_uncertainty_score":0.7642035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008491999688964535,"score_gpt":0.2465649185336351,"score_spread":0.2380729188446706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}